ArticleJournal of nanobiotechnology2026
Improving wound healing function and storage stability of stem cell-derived extracellular vesicles via lyophilized hyaluronic acid formulation.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bridging Scales: Integrating Hyaluronan-Based Nanoencapsulation into 3D Hydrogel Constructs for Advanced Therapeutics-A Comprehensive Review.Gels (Basel, Switzerland) · 2026Review
- Extracellular Vesicles in Wearable Delivery Systems for Cosmeceutical Applications.Advanced healthcare materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Although therapeutic extracellular vesicles (EVs) hold great promise for clinical applications, their limited targeting efficiency and poor storage stability remain critical barriers to clinical translation. Here, we present a lyophilized hyaluronic acid (HA)-coated formulation of EVs derived from human adipose stem cells, engineered to enhance both therapeutic efficacy and long-term preservation. This formulation leverages the natural affinity between HA and the CD44 proteins expressed on the EV membranes, forming stable HA-EV complexes that remain intact following lyophilization and rehydration. These HA-EVs exhibited superior targeting of CD44-expressing cells, including pro-inflammatory macrophages and senescent dermal fibroblasts, thereby effectively suppressing inflammatory responses and restoring fibroblast function in a wound-healing mouse model. Notably, HA-EVs significantly accelerate wound healing by promoting collagen synthesis within the dermal layer, outperforming bare EVs. Furthermore, HA served as an effective cryoprotectant, preserving the physicochemical and biological integrity of EVs for at least six months at 4 ℃. Taken together, our results establish lyophilized HA-EVs as a robust and clinically translatable platform that integrates cell-specific targeting with long-term storage stability for regenerative medicine applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.